The National Institute of Health’s Countermeasures Against Chemical Threats (CounterACT) is seeking feedback from industry regarding the potential convening of a meeting to facilitate partnerships between active NIH CounterACT investigators and entities from the commercial and industrial sectors.
Many NIH CounterACT projects are developing candidate therapeutics and are now poised for more advanced development activities, including pre-Investigational New Drug (pre-IND)-enabling and clinical studies that could be supported by other federal agencies that fund advanced development, FDA approval and licensure, as well as procurement activities under Project BioShield.
The majority of current projects supported by NIH are in academic labs that often do not possess the resources and expertise for these types of advanced studies. To address this need, it is critical that the NIH facilitate partnerships between academic laboratories and pharmaceutical or biotechnology companies that typically have more experience in drug development and regulatory approval.
If there is general interest in an Investigator-Industry Partnership meeting, more information about specific projects that are ready for engagement from industry will be provided.
Further details are available via RFI Announcement: NOT-NS-16-005. The response deadline is February 29, 2016.